Skip to main content

Advertisement

Log in

Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV

  • HIV Pathogenesis and Treatment (AL Landay and N Utay, Section Editors)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Abnormal liver enzymes (LE) are common in patients infected with the human immunodeficiency virus (HIV) even in the absence of viral hepatitis or alcohol abuse. With availability of antiretroviral combination therapy, life expectancy has improved dramatically and as a consequence the spectrum of liver disease is changing. Increased reports on the development of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in HIV coinfected patients raise questions around prevalence, clinical manifestations, and clinical outcome of these liver diseases in HIV coinfection. Moreover, the potential impact of combination antiretroviral therapy as well as direct HIV effects on the emergence of non-alcoholic fatty liver disease needs to be explored. This review summarizes the recent literature on NAFLD and NASH in HIV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Serrano-Villar S, Gutiérrez F, Miralles C, et al. Human immunodeficiency virus as a chronic disease: evaluation and management of nonacquired immune deficiency syndrome-defining conditions. Open Forum Infect Dis. 2016;3(2):ofw097.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sebastiani G, Rollet-Kurhajec KC, Pexos C, Gilmore N, Klein MB. Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis. 2015;2(1):ofv015.

    Article  PubMed  PubMed Central  Google Scholar 

  3. •• Morse CG, McLaughlin M, Matthews L, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60(10):1569–78.2. One of the few liver biopsy studies in HIV-infected adults with aminotransferase levels elevated above the upper limit of normal for ≥6 months while receiving ART, and without chronic viral hepatitis or other known causes of chronic liver disease. Interestingly, HIV-infected adults with chronic aminotransferase elevations while receiving ART had a high rate of liver disease (55% NASH)

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Macias J, Rivero-Juarez A, Neukam K, et al. HEPAVIR study group. Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. AIDS. 2015;29(15):1927–35.

    Article  CAS  PubMed  Google Scholar 

  5. Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the multicenter AIDS cohort study. Am J Gastroenterol. 2014;109(5):695–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rivero-Juárez A, Camacho A, Merchante N, et al. Grupo para el estudio de las hepatitis vı’ricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One. 2013;8(7):e68953.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50(5):464–73.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained aminotransferase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009;49:436–42.

    Article  PubMed  Google Scholar 

  9. •• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. Clinically extremely useful guidelines around all major aspects of fatty liver disease including disease definitions and treatment recommendations .

  10. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84.

    Article  PubMed  Google Scholar 

  11. Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol. 2013;47:182–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Vuille-Lessard É, Lebouché B, Lennox L, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS. 2016;30:2635–43.

    Article  PubMed  Google Scholar 

  13. Trépo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver diseases. J Hepatol. 2016;65:399–412.

    Article  PubMed  Google Scholar 

  14. Macías J, Real LM, Rivero-Juárez A, et al. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. HIV Med. 2016.

  15. Vodkin I, Valasek MA, Bettencourt R, et al. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41(4):368–78.

    Article  CAS  PubMed  Google Scholar 

  16. Scheiner B, Mandorfer M, Schwabl P, et al. The impact of PNPLA3 rs738409 SNP on liver fibrosis progression, portal hypertension and hepatic steatosis in HIV/HCV coinfection. PLoS One. 2015;10(11):e0143429.

    Article  PubMed  PubMed Central  Google Scholar 

  17. •• Jiménez-Sousa MA, Berenguer J, García-Álvarez M, et al. Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients. AIDS. 2016;30(3):465–70. This cross-sectional study analyses the association between patatin-like phospholipase domain-containing 3 gene (PNPLA3) rs738409 polymorphism and severity of liver disease in HIV/hepatitis C virus-coinfected patient. Indeed, PNPLA3 rs738409 polymorphism was associated with the severity of liver fibrosis in patients coinfected with HIV and hepatitis C virus, suggesting that this polymorphism might also play a significant role in the progression of hepatic fibrosis in this group of patients

    Article  PubMed  Google Scholar 

  18. Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5(9):782–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lelouvier B, Servant F, Païssé S, et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. Hepatology. 2016; doi:10.1002/hep.28829.

    PubMed  Google Scholar 

  20. Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two way street. AIDS. 2016;14.

  21. Liu JP, Zou WL, Chen SJ, et al. Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development. World J Gastroenterol. 2016;22(32):7353–64.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Rial SA, Karelis AD, Bergeron KF, et al. Gut microbiota and metabolic health: the potential beneficial effects of a medium chain triglyceride diet in obese individuals. Nutrients. 2016;8(5).

  23. Houghton D, Thoma C, Hallsworth K, et al. Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2016.

  24. Pérez-Matute P, Pérez-Martínez L, Aguilera-Lizarraga J, et al. Maraviroc modifies gut microbiota composition in a mouse model of obesity: a plausible therapeutic option to prevent metabolic disorders in HIV-infected patients. Rev Esp Quimioter. 2015;28(4):200–6.

    PubMed  Google Scholar 

  25. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16:F1–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Noor MA, Parker RA, O’Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137–44.

    Article  CAS  PubMed  Google Scholar 

  27. Shlay JC, Visnegarwala F, Bartsch G, et al. Terry Beirn community programs for clinical research on AIDS (CPCRA). Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147–55.

    Article  CAS  PubMed  Google Scholar 

  28. Pedersen KK, Pedersen M, Trøseid M, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr. 2013;64:425–33.

    Article  CAS  PubMed  Google Scholar 

  29. Adeyemi OM, Livak B, Orsi J, et al. Vitamin D and insulin resistance in non-diabetic women's interagency HIV study participants. AIDS Patient Care STDs. 2013;27:320–5.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Lemoine M, Barbu V, Girard PM, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS. 2006;20:387–95.

    Article  CAS  PubMed  Google Scholar 

  31. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47:250–7.

    Article  PubMed  Google Scholar 

  32. Akhtar MA, Mathieson K, Arey B, et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol. 2008;20:1194–204.

    Article  CAS  PubMed  Google Scholar 

  33. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat. 2011;18:11–6.

    Article  CAS  PubMed  Google Scholar 

  34. Stankov MV, Panayotova-Dimitrova D, Leverkus M, Vondran FW, Bauerfeind R, Binz A, Behrens GM. Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation. AIDS. 2012;26:1995–2006.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the DZIF TTU HIV Project 05.803 and the German Center for Infection Research (DZIF).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jürgen Kurt Rockstroh.

Ethics declarations

Conflict of Interest

Jürgen Kurt Rockstroh reports honoraria for speaking at educational events or consulting from Abbott, Abbvie, Bionor, BMS, Cipla, Gilead, Hexal, Janssen, Merck, and ViiV.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on HIV Pathogenesis and Treatment

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rockstroh, J.K. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV. Curr HIV/AIDS Rep 14, 47–53 (2017). https://doi.org/10.1007/s11904-017-0351-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-017-0351-2

Keywords

Navigation